Plus   Neg

AXIM' Partner Empowered Files EUA With FDA For Use Of Rapid COVID-19 Neutralizing Antibody Test

AXIM Biotechnologies Inc. (AXIM.OB) said that its manufacturing partner, Empowered Diagnostics, has filed an Emergency Use Authorization or EUA application with the US Food and Drug Administration for the approval to use ImmunoPass, the company's rapid test that semi-quantitatively measures levels of COVID-19 neutralizing antibodies, to detect COVID-19 neutralizing antibodies in whole blood at point-of-care locations.

AXIM said earlier this month that it completed clinical trials, identifying that operators found ImmunoPass easy to use and that they encountered no issues in using the company's test to measure participants' levels of COVID-19 neutralizing antibodies.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
A third of those American adults now refusing to get vaccinated would get vaccinated if they could take a pill instead of getting the vaccine shot, according to a poll conducted by Quadrant Strategies and commissioned by biotechnology company Vaxart, Inc. A pill vaccine is expected to overcome vaccine resistance of millions of Americans. While reporting financial results for the first quarter on Thursday, Biogen Inc. (BIIB) raised its adjusted earnings guidance for the full-year 2021, but maintained revenue outlook. For fiscal 2021, the company raised its adjusted earnings guidance to a range of $17.50 to $19.00 per share from the... While reporting financial results for the first quarter on Thursday, electric utility American Electric Power Co., Inc. (AEP) reaffirmed its fiscal 2021 operating earnings guidance in the range of $4.55 to $4.75 per share. Including special items, estimated earnings would be between $4.56 and $4.76 per...
Follow RTT